Back
CE / CME
Integrating Genotype Into Counseling and Management Planning in Pediatric Sensorineural Hearing Loss: The Role of Genetic Counselors
Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit
Physicians: maximum of 0.50 AMA PRA Category 1 Credit™
Nurse Practitioners/Nurses: 0.50 Nursing contact hour
Genetic Counselors: 0.50 CEUs or 0.50 Category 1 Contact Hour
Released: July 13, 2026
Expiration: July 12, 2027
Activity
Genetic Counseling in Pediatric SNHL
More families of children with genetic SNHL are asking about gene therapy, current clinical trials, and future treatment options. These conversations can be challenging for genetic counselors because the therapeutic landscape is evolving quickly and eligibility for novel therapies is highly genotype specific.15 Furthermore, media coverage may blur distinctions among approved and investigational therapies, expanded access pathways, and preclinical research.
Yet genetic counselors are well positioned to help families understand what a confirmed molecular diagnosis does and does not mean for their child’s future. This includes clarifying if an approved therapy is relevant, managing expectations about benefits and uncertainties, addressing cost and access barriers, and coordinating referrals to audiology, otolaryngology, early intervention, and specialized treatment centers.16
Patient Case 2: Lucas, 7-Month-Old Boy With OTOF-Related Hearing Loss
Your next patient is Lucas, a 7-month-old boy who was referred after his newborn hearing screening. Diagnostic auditory brainstem response confirmed bilateral severe to profound SNHL. Lucas was fit with hearing aids at 3 months of age, but aided responses remain limited. Early intervention services were started. Lucas’ current care team includes audiology, otolaryngology, early intervention, and genetics.
Comprehensive gene panel testing for hearing loss identifies biallelic pathogenic variants in OTOF gene that are consistent with OTOF-related hearing loss, an autosomal and recessive nonsyndromic auditory synaptopathy.17
His parents have read online about gene therapy for genetic hearing loss. They ask, “Does this mean Lucas can get gene therapy instead of cochlear implant? Will insurance pay for it? Should we wait before moving forward with other interventions?”
Balanced, Evidence-Based Counseling on Gene Therapy
The first task in counseling families about gene therapy is to anchor the discussion in the patient’s molecular diagnosis. Gene therapy is not a general treatment for all genetic hearing loss cases, and eligibility depends on patients’ specific gene mutation, variant, and inheritance pattern; severity and configuration of hearing loss; cochlear anatomy (ie, hair cell function); age; developmental status; and prior cochlear implant. Use of gene therapy further depends on its regulatory status and other treatment-center factors.18 Additional clinical criteria are important and must not be overlooked.
For Lucas, counseling his parents on gene therapy is relevant because of the FDA’s approval of lunsotogene parvec-cwha. As mentioned, this gene therapy is indicated to treat pediatric and adult patients with severe to profound or profound OTOF-related hearing loss. To qualify, patients must have molecularly confirmed biallelic OTOF variants, preserved cochlear outer hair cell function, and no prior cochlear implant in the affected ear.13,14
Therefore, genetic counselors must avoid making the leap from potentially relevant for patients to eligible and expected to provide benefit. A balanced statement to share with Lucas’ family in gene therapy counseling might be: “Lucas’s genetic testing results confirm his diagnosis of OTOF-related hearing loss, for which a gene therapy was recently approved. That makes a referral to a center experienced in OTOF-related treatment appropriate. However, eligibility for gene therapy is not solely determined by genetic testing results. The treatment team will need to review Lucas’s ear-specific findings, hearing profile, prior interventions, and other relevant criteria to determine his eligibility.”
Approved Vs Investigational SNHL Interventions
Because families often use the term “gene therapy” broadly, genetic counselors must ensure they understand the categories that identify SNHL interventions as approved, investigational, or available via compassionate use or expanded access.
An approved therapy has a regulatory indication from the FDA for a defined population. For OTOF-related hearing loss, the FDA’s accelerated approval of lunsotogene parvec-cwha means that this gene therapy is no longer purely theoretical or investigational.
In turn, investigational therapies are those that are in clinical development. That means clinical trials are underway to evaluate the specific therapy’s safety, efficacy, dosing, delivery, and durability within a defined patient population. A trial may involve a therapy that is showing promise but not yet approved for a given indication or patient population.
Before therapies become investigational or subsequently approved, they are first studied in preclinical research. This is where animal models, vector development, delivery studies, and early translational work occur. Of note, preclinical research should not be presented to families as an available treatment pathway.
Finally, there are some therapies that are approved for use under strict, last-resort conditions called expanded access or compassionate use. Expanded access pathways may be considered when patients have a serious or life-threatening condition with no satisfactory alternatives. This pathway allows healthcare professionals to access investigational therapies for specific, qualifying patients without clinical trial participation. This also means that the therapy may not provide benefit to patients because it is still under investigation. Availability under expanded access depends on regulatory requirements, institutional processes, and patient-specific factors. It should not be presented to families as guaranteed access or benefit.19,20
A family-friendly explanation to Lucas’ parents may include: “Although a gene therapy is approved for a specific genetic hearing loss diagnosis, others are being studied in clinical trials and many more are still at the laboratory stage. The next step is not to simply ask whether gene therapy exists. Instead, we need to determine if there is an approved or trial-based option for Lucas’ exact genotype and clinical profile.”
Feedback on Question 6
Lucas’s confirmed genotype makes an evaluation for gene therapy appropriate but does not automatically establish his eligibility or guarantee benefit. Genetic counselors should support timely referral to an experienced treatment center, while reinforcing continued hearing access and language-supportive planning. Cochlear implant evaluation may be coordinated with gene therapy evaluation, especially since prior implant can affect eligibility. Furthermore, an open-ended pause in standard care is not appropriate.
Managing Expectations in an Evolving Therapeutic Landscape
Families may hear dramatic stories in the media or from other individuals with genetic hearing loss about the benefit of gene therapy. Although these reports can generate hope appropriately, they also may create therapeutic misconception. This is especially true for families who assume that therapy benefit is predictable, immediate, durable, or broadly applicable.
This is where genetic counselors can help families understand 4 key points. First, OTOF-directed gene therapy does not apply to all forms of genetic hearing loss. Second, even with the newly approved OTOF-directed gene therapy, treatment center review is needed to confirm patients’ eligibility. Third, outcomes can vary across patients and the long-term durability and comparative outcomes of gene therapy for genetic hearing loss will continue to be studied. Fourth, early intervention, audiology follow-up, communication support, and otolaryngology care remain important regardless of gene therapy evaluation conclusions.
For children with a different genotype, such as biallelic GJB2 variants, counseling on gene therapy would be different. That means an approved OTOF-directed therapy should not be recommended to patients without OTOF-related hearing loss. Families might ask about research despite their child not having OTOF-related hearing loss, so counseling should distinguish current indications from future possibilities.
Addressing Common Barriers to Gene Therapy
After counseling on gene therapy, families often ask practical questions, such as:
- “Will insurance cover this?”
- “What if treatment is only available at a few centers?”
- “Do we have to travel to receive treatment?”
- “Will this affect our insurance coverage for cochlear implant?”
- “What costs are expected to be out of pocket?”
- “What happens if treatment is approved but not available in our state?”
Genetic counselors are not expected to resolve every question or concern about access and cost during visits. Rather, they should normalize these concerns and connect families with the right resources.
A comprehensive counseling plan may include referral to a treatment center or otology/neurotology team familiar with OTOF-directed gene therapy. Genetic counselors also should review health insurance coverage requirements and prior authorization processes and involve social work, financial counseling, or patient navigation as needed to support families. Of note, coverage policies may differ from FDA approvals. Furthermore, they can discuss travel, lodging, time off work, childcare, and follow-up requirements. Finally, coordination with audiology and cochlear implant teams is important so that gene therapy evaluation does not disrupt timely care with established interventions.
A useful statement to share with Lucas’ parents may be: “FDA approval does not equal automatic access. The next step is to connect you with an experienced treatment center that can assess Lucas’s eligibility and help determine coverage, prior authorization needs, and logistical requirements. We should also keep his hearing intervention planning on track so that access and reimbursement questions do not delay his spoken language development.”
Feedback on Question 7
Gene therapy counseling must be genotype specific. That means an OTOF-directed gene therapy should not be recommended to Amara because she has GJB2-related hearing loss. Genetic counselors should validate the family’s questions, explain the distinction between Amara’s genotype and OTOF-directed gene therapy, and preserve timely access to standard care. It is appropriate to discuss research cautiously but not to imply that future trials, expanded access, or health insurance exceptions are likely or guaranteed for Amara.
Clarifying Referral Pathways and Interdisciplinary Coordination
Genetic testing that confirms a molecular diagnosis for hearing loss should then trigger a coordinated, multidisciplinary care plan, not a single conversation held with families in isolation. Going back to our patient case with Lucas, a practical referral pathway for him first includes genetic counseling with an expert who can interpret genetic testing results to confirm his inheritance pattern, recurrence risk, family testing, and implications for siblings or future pregnancies for the family. Then coordination with otolaryngology and/or neurotology is necessary to assess Lucas’ candidacy for cochlear implant and gene therapy. These care team members also can review his ear anatomy and support surgical timing.
Multidisciplinary care with audiology is critical, too. These folks will continue hearing aid verification and testing and auditory development monitoring via ear-specific measures relevant to treatment planning. Then early interventions and speech-language services can help maintain language access planning regardless of treatment evaluation status.
Referrals should also be made to treatment centers with OTOF-directed gene therapy expertise for Lucas. They will determine if he meets the current criteria and discuss the procedures, risks, expected follow-up, and alternatives available.
If available in your institution or community, referral to financial counseling, social work, and/or patient navigation can help families address barriers to insurance coverage, including prior authorization requirements. These care team members can also support families with travel, lodging, employment constraints, and other barriers.
Like the ACMG’s clinical practice resource on hearing loss emphasizes, an etiologic diagnosis is critical because it can inform patient education, genetic testing and counseling, and management planning, thereby supporting the need for multidisciplinary care.6
Conclusion
Families asking about gene therapy during genetic counseling require more than a simple yes or no. They need help in understanding whether the gene therapy applies to their child’s genotype, if their child meets the eligibility criteria, on what remains uncertain, and how treatment exploration fits alongside established, standard care.
For OTOF-related hearing loss, the FDA approval of lunsotogene parvec-cwha makes genotype-specific therapy evaluation clinically relevant for appropriately selected patients. For other genetic etiologies, such as GJB2, an OTOF-directed gene therapy should not be recommended. Regardless, genetic counselors should support families by preserving timely access to hearing interventions and employing multidisciplinary management, while helping them navigate the current evidence, expectations, barriers, and referral pathways.